STAND.
COM. REP. NO. 1722-24
Honolulu, Hawaii
, 2024
RE: H.R. No. 174
H.D. 1
Honorable Scott K. Saiki
Speaker, House of Representatives
Thirty-Second State Legislature
Regular Session of 2024
State of Hawaii
Sir:
Your Committee on Judiciary & Hawaiian Affairs, to which was referred H.R. No. 174 entitled:
"HOUSE RESOLUTION REQUESTING THE DEPARTMENT OF THE ATTORNEY GENERAL TO CONDUCT A STUDY TO DETERMINE IF XYLAZINE TESTING STRIPS SHOULD BE EXCLUDED FROM THE STATE'S DEFINITION OF DRUG PARAPHERNALIA,"
begs leave to report as follows:
Your Committee finds that there has been a sharp increase in the trafficking of fentanyl mixed with xylazine. Xylazine, also known as "Tranq," is a powerful sedative that the United States Food and Drug Administration has approved for veterinary use only. Your Committee further finds that since xylazine is not an opioid, overdose reversal agents such as naloxone do not counteract the effects of xylazine. This places users at a higher risk of suffering from a fatal drug poisoning. People who inject drug mixtures containing xylazine can also develop severe wounds, including necrosis, that may lead to amputation. Your Committee believes that xylazine testing strips could prevent these complications and save lives by allowing users to test their drugs for xylazine before administration.
As affirmed by the record of votes of the members of your Committee on Judiciary & Hawaiian Affairs that is attached to this report, your Committee concurs with the intent and purpose of H.R. No. 174, as amended herein, and recommends its adoption in the form attached hereto as H.R. No. 174, H.D. 1.
Respectfully submitted on behalf of the members of the Committee on Judiciary & Hawaiian Affairs,
|
|
____________________________ DAVID A. TARNAS, Chair |
|
|
|